Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Schedule of Stock Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total stock-based compensation expense	$ 1,256,000	$ 2,103,000
Stock Option [Member]
Total stock-based compensation expense	1,256,000	2,103,000
Tax benefit
Stock based compensation expense, net of tax	1,256,000	2,103,000
Stock Option [Member] \| Research and Development Expense [Member]
Total stock-based compensation expense	744,000	1,032,000
Stock Option [Member] \| General and Administrative Expenses [Member]
Total stock-based compensation expense	512,000	1,071,000
Restricted Stock [Member]
Total stock-based compensation expense	464,000	172,000
Tax benefit
Stock based compensation expense, net of tax	464,000	172,000
Restricted Stock [Member] \| Research and Development Expense [Member]
Total stock-based compensation expense	325,000
Restricted Stock [Member] \| General and Administrative Expenses [Member]
Total stock-based compensation expense	$ 139,000	$ 172,000